On thin ice: Barriers to adoption of surveillance for patients with stage I testicular seminoma. Survey of US radiation oncologists

Aditya Jain, Catherine Degnin, Yiyi Chen, Mike Craycraft, Arthur Hung, Jerry Jaboin, Charles Thomas, Timur Mitin

Research output: Contribution to journalArticle

Abstract

Purpose: Most men with stage I testicular seminoma are cured with surgery alone, which is a preferred strategy per national guidelines. The current pattern of practice among US radiation oncologists (ROs) is unknown. Materials and Methods: We surveyed practicing US ROs via an online questionnaire. Respondent's characteristics, self-rated knowledge, perceived patient compliance rates with observation were analyzed for association with treatment recommendations. Results: We received 353 responses from ROs, of whom 23% considered themselves experts. A vast majority (84%) recommend observation as a default strategy, however this rate drops to 3% if the patient is believed to be noncompliant. 33% of respondents believe that survival is jeopardized in case of disease recurrence, and among these respondents only 5% support observation. 22% of respondents over-estimate the likelihood of noncompliance with observation to be in the 50-80% range. Responders with a higher perceived noncompliance rate are more likely to recommend adjuvant therapy (Fisher's exact p<0.01). Only 7% of respondents recommend observation for stage IS seminoma and 45% administer adjuvant RT in patients with elevated pre-orchiectomy alpha-fetal protein levels. Conclusions: Many US ROs over-estimate the likelihood that stage I testicular seminoma patients will be noncompliant with surveillance and incorrectly believe that overall survival is jeopardized if disease recurs on surveillance. Observation is quickly dismissed for patients who are not deemed to be compliant with observation, and is generally not accepted for patients with stage IS disease. There is clearly an opportunity for improved physician education on evidence-based management of stage I testicular seminoma.

Original languageEnglish (US)
Pages (from-to)452-460
Number of pages9
JournalInternational Braz J Urol
Volume44
Issue number3
DOIs
StatePublished - May 1 2018

Fingerprint

Seminoma
Ice
Observation
Fetal Proteins
Survival
Orchiectomy
Patient Compliance
Surveys and Questionnaires
Radiation Oncologists
Guidelines
Physicians
Education
Recurrence
Therapeutics

Keywords

  • Chemotherapy,adjuvant
  • Health care surveys
  • Radiotherapy
  • Seminoma

ASJC Scopus subject areas

  • Urology

Cite this

@article{87b1ef721e67487d92387e5db53accd2,
title = "On thin ice: Barriers to adoption of surveillance for patients with stage I testicular seminoma. Survey of US radiation oncologists",
abstract = "Purpose: Most men with stage I testicular seminoma are cured with surgery alone, which is a preferred strategy per national guidelines. The current pattern of practice among US radiation oncologists (ROs) is unknown. Materials and Methods: We surveyed practicing US ROs via an online questionnaire. Respondent's characteristics, self-rated knowledge, perceived patient compliance rates with observation were analyzed for association with treatment recommendations. Results: We received 353 responses from ROs, of whom 23{\%} considered themselves experts. A vast majority (84{\%}) recommend observation as a default strategy, however this rate drops to 3{\%} if the patient is believed to be noncompliant. 33{\%} of respondents believe that survival is jeopardized in case of disease recurrence, and among these respondents only 5{\%} support observation. 22{\%} of respondents over-estimate the likelihood of noncompliance with observation to be in the 50-80{\%} range. Responders with a higher perceived noncompliance rate are more likely to recommend adjuvant therapy (Fisher's exact p<0.01). Only 7{\%} of respondents recommend observation for stage IS seminoma and 45{\%} administer adjuvant RT in patients with elevated pre-orchiectomy alpha-fetal protein levels. Conclusions: Many US ROs over-estimate the likelihood that stage I testicular seminoma patients will be noncompliant with surveillance and incorrectly believe that overall survival is jeopardized if disease recurs on surveillance. Observation is quickly dismissed for patients who are not deemed to be compliant with observation, and is generally not accepted for patients with stage IS disease. There is clearly an opportunity for improved physician education on evidence-based management of stage I testicular seminoma.",
keywords = "Chemotherapy,adjuvant, Health care surveys, Radiotherapy, Seminoma",
author = "Aditya Jain and Catherine Degnin and Yiyi Chen and Mike Craycraft and Arthur Hung and Jerry Jaboin and Charles Thomas and Timur Mitin",
year = "2018",
month = "5",
day = "1",
doi = "10.1590/S1677-5538.IBJU.2017.0454",
language = "English (US)",
volume = "44",
pages = "452--460",
journal = "International braz j urol : official journal of the Brazilian Society of Urology",
issn = "1677-5538",
publisher = "Brazilian Society of Urology",
number = "3",

}

TY - JOUR

T1 - On thin ice

T2 - Barriers to adoption of surveillance for patients with stage I testicular seminoma. Survey of US radiation oncologists

AU - Jain, Aditya

AU - Degnin, Catherine

AU - Chen, Yiyi

AU - Craycraft, Mike

AU - Hung, Arthur

AU - Jaboin, Jerry

AU - Thomas, Charles

AU - Mitin, Timur

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Purpose: Most men with stage I testicular seminoma are cured with surgery alone, which is a preferred strategy per national guidelines. The current pattern of practice among US radiation oncologists (ROs) is unknown. Materials and Methods: We surveyed practicing US ROs via an online questionnaire. Respondent's characteristics, self-rated knowledge, perceived patient compliance rates with observation were analyzed for association with treatment recommendations. Results: We received 353 responses from ROs, of whom 23% considered themselves experts. A vast majority (84%) recommend observation as a default strategy, however this rate drops to 3% if the patient is believed to be noncompliant. 33% of respondents believe that survival is jeopardized in case of disease recurrence, and among these respondents only 5% support observation. 22% of respondents over-estimate the likelihood of noncompliance with observation to be in the 50-80% range. Responders with a higher perceived noncompliance rate are more likely to recommend adjuvant therapy (Fisher's exact p<0.01). Only 7% of respondents recommend observation for stage IS seminoma and 45% administer adjuvant RT in patients with elevated pre-orchiectomy alpha-fetal protein levels. Conclusions: Many US ROs over-estimate the likelihood that stage I testicular seminoma patients will be noncompliant with surveillance and incorrectly believe that overall survival is jeopardized if disease recurs on surveillance. Observation is quickly dismissed for patients who are not deemed to be compliant with observation, and is generally not accepted for patients with stage IS disease. There is clearly an opportunity for improved physician education on evidence-based management of stage I testicular seminoma.

AB - Purpose: Most men with stage I testicular seminoma are cured with surgery alone, which is a preferred strategy per national guidelines. The current pattern of practice among US radiation oncologists (ROs) is unknown. Materials and Methods: We surveyed practicing US ROs via an online questionnaire. Respondent's characteristics, self-rated knowledge, perceived patient compliance rates with observation were analyzed for association with treatment recommendations. Results: We received 353 responses from ROs, of whom 23% considered themselves experts. A vast majority (84%) recommend observation as a default strategy, however this rate drops to 3% if the patient is believed to be noncompliant. 33% of respondents believe that survival is jeopardized in case of disease recurrence, and among these respondents only 5% support observation. 22% of respondents over-estimate the likelihood of noncompliance with observation to be in the 50-80% range. Responders with a higher perceived noncompliance rate are more likely to recommend adjuvant therapy (Fisher's exact p<0.01). Only 7% of respondents recommend observation for stage IS seminoma and 45% administer adjuvant RT in patients with elevated pre-orchiectomy alpha-fetal protein levels. Conclusions: Many US ROs over-estimate the likelihood that stage I testicular seminoma patients will be noncompliant with surveillance and incorrectly believe that overall survival is jeopardized if disease recurs on surveillance. Observation is quickly dismissed for patients who are not deemed to be compliant with observation, and is generally not accepted for patients with stage IS disease. There is clearly an opportunity for improved physician education on evidence-based management of stage I testicular seminoma.

KW - Chemotherapy,adjuvant

KW - Health care surveys

KW - Radiotherapy

KW - Seminoma

UR - http://www.scopus.com/inward/record.url?scp=85049023869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049023869&partnerID=8YFLogxK

U2 - 10.1590/S1677-5538.IBJU.2017.0454

DO - 10.1590/S1677-5538.IBJU.2017.0454

M3 - Article

C2 - 29522295

AN - SCOPUS:85049023869

VL - 44

SP - 452

EP - 460

JO - International braz j urol : official journal of the Brazilian Society of Urology

JF - International braz j urol : official journal of the Brazilian Society of Urology

SN - 1677-5538

IS - 3

ER -